Pharma: Going hand-in-hand... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Going hand-in-hand...

Jan 9, 2007

The 'partnership' model for introducing patented and generic drugs has emerged as the new mantra for pharmaceutical companies in recent times. And we are not talking about only Indian pharma companies, but global pharma players as well. Increased competition, ballooning R&D budgets, regulatory policy changes and pressures to prune costs and improve profitability has meant that pharma companies worldwide have had to dig deeper and come out with strategies to sustain growth in this highly competitive environment. Global pharma: Jumping the 'partnership' bandwagon...

Increased pressures on the R&D front have plagued global innovators such as Pfizer, GlaxoSmithKline Plc, Merck, Sanofi-Aventis and BMS amongst others. On one hand, their existing blockbuster drugs (having annual sales of US$ 1 bn and more) are losing patent protection ushering in generic competition, while on the other hand their research pipeline has been drying up. Pfizer's recent discontinuance of the much-hyped drug 'torcetripib' has brought to the fore the increased dependence of Big Pharma on blockbuster drugs. Consequently, to boost the product pipeline, many of these companies are either looking to ally with innovator firms in new drug development or in-license the potential drug candidates from smaller firms. This trend has particularly been evident in the case of biotech drugs.

Increased competition and price erosion in the generics space have also prompted global generic players to partner with companies in India, which enjoy a low cost advantage to effectively compete and launch generic drugs in the global generics market.

Indian pharma: 'Partnership' fever also catching on

Most of the Indian companies are focusing on the global generics market to propel revenues and have yet to make a significant headway in new drug discovery research. Because of the high level of competition and resource constraints, the partnership model has been gaining considerable ground. These have mostly been in the following areas:

Discovery research: Considering that discovery research is a high-risk, high-return business, Indian pharma companies have been either collaborating with global pharma companies or out-licensing their molecules in light of the huge investment involved and uncertainty in the outcome.

Authorised generics: Indian companies like Dr.Reddy's have entered into authorised generics deals with global innovators to capitalise on the lucrative 180-day exclusivity to drive revenues and profits.

In-licensing: In the product patent era, in-licensing agreements with global pharma companies are beneficial in stepping up new product launches in the country. Indian players are leveraging on their strong marketing and distribution network to launch the products of global innovators in the domestic market and also keep the product portfolio fresh.

The way forward...
There are pros and cons for both global and Indian players. For instance, global pharma majors are looking to in-license potential NCEs in the medium term to complement their product pipeline. However, due to increased demand for these potential drugs, the amount of milestone payments to be paid is expected to increase. Besides this, the royalties on sales will also increase proving to be a negative for Big Pharma. However, as far as Indian pharma is concerned, given the resource crunch, willingness of Indian pharma companies to bring outside expertise to the table for drug development should be construed as a positive step to stabilise revenues and profitability. For both, however, because the revenues will be shared, the potential upside gets capped. Nevertheless, considering the fact that conditions in the global pharma market are getting increasingly tough, partnerships will go a long way in sustaining growth and ensuring stability in the long term.


Equitymaster requests your view! Post a comment on "Pharma: Going hand-in-hand...". Click here!

  

More Views on News

GSK PHARMA Share Price Down by 5%; BSE HEALTHCARE Index Up 3.8% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

GSK PHARMA share price is trading down by 5% and its current market price is Rs 1,785. The BSE HEALTHCARE is up by 3.8%. The top gainers in the BSE HEALTHCARE Index are NATCO PHARMA (up 15.8%) and DR. REDDYS LAB (up 12.0%). The top losers is GSK PHARMA (down 5.1%)..

ASTER DM HEALTHCARE LTD Share Price Up by 8%; BSE HEALTHCARE Index Up 3.3% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

ASTER DM HEALTHCARE LTD share price is trading up by 8% and its current market price is Rs 148. The BSE HEALTHCARE is up by 3.3%. The top gainers in the BSE HEALTHCARE Index are ASTER DM HEALTHCARE LTD (up 7.7%) and DR. REDDYS LAB (up 9.9%). The top losers are ALKEM LABORATORIES (down 0.1%) and FORTIS HEALTHCARE (down 1.6%).

ASTRAZENECA PHARMA Share Price Up by 6%; BSE HEALTHCARE Index Up 4.1% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

ASTRAZENECA PHARMA share price is trading up by 6% and its current market price is Rs 4,548. The BSE HEALTHCARE is up by 4.1%. The top gainers in the BSE HEALTHCARE Index are ASTRAZENECA PHARMA (up 6.3%) and DR. REDDYS LAB (up 9.1%). The top losers are FORTIS HEALTHCARE (down 0.1%) and ALEMBIC PHARMA (down 0.4%).

GRANULES INDIA Share Price Up by 5%; BSE HEALTHCARE Index Up 4.5% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

GRANULES INDIA share price is trading up by 5% and its current market price is Rs 385. The BSE HEALTHCARE is up by 4.5%. The top gainers in the BSE HEALTHCARE Index are GRANULES INDIA (up 5.0%) and DR. REDDYS LAB (up 8.8%). The top losers are ALEMBIC PHARMA (down 0.1%) and GSK PHARMA (down 0.3%).

J.B.CHEMICALS at All Time High; BSE HEALTHCARE Index Up 4.3% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

J.B.CHEMICALS share price has hit an all time high at Rs 1,148 (up 7.2%). The BSE HEALTHCARE Index is up by 4.3%. Among the top gainers in the BSE HEALTHCARE Index today are J.B.CHEMICALS (up 7.2%) and ABBOTT INDIA (up 0.8%). The top losers include FORTIS HEALTHCARE (down 0.2%) and PIRAMAL ENTERPRISES (down 0.7%).

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 18, 2020 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS